Skip to content
LATEST
Health

New Prostate Cancer Screening Guidelines Recommend Routine PSA Testing

New guidelines recommend routine biennial PSA screening for average-risk men aged 50–69, with earlier and more frequent testing for high-risk groups to…

New Prostate Cancer Screening Guidelines Recommend Routine PSA Testing

Updated clinical guidelines now recommend routine prostate-specific antigen (PSA) screening for men aged 50 to 69 at average risk, with testing intervals set at two years. This policy shift marks a departure from previous guidance, which favored shared decision-making over universal screening recommendations. The updated framework aims to balance early detection of aggressive malignancies with the mitigation of overdiagnosis and overtreatment risks.

High-risk populations, including Black men and those with specific family histories, are advised to initiate annual screening at age 45. For men aged 70 to 74, the decision to continue screening is subject to individual clinical consultation, while routine screening is generally not recommended for individuals aged 75 and older.

United States

The updated protocol introduces diagnostic guardrails to manage potential harms. If initial PSA levels exceed established thresholds—3 ng/mL for men under 70 and 6.5 ng/mL for those 70 and older—repeat testing is required before further intervention. Subsequent diagnostic steps prioritize non-invasive methods, such as prostate MRI or biomarker testing, reserving biopsies for cases with high clinical suspicion.

These recommendations are intended to address the high

For patients diagnosed with low-risk prostate cancer, the guidelines emphasize active surveillance as the primary management strategy to avoid unnecessary medical procedures. These recommendations are intended to address the high incidence of prostate cancer, which remains the second leading cause of cancer-related mortality among men in the United States. Approximately 334,000 new diagnoses and 36,320 deaths are projected for 2026.

These updated standards arrive as federal health authorities undergo significant leadership transitions and internal restructuring. The alignment or divergence of these new guidelines with future federal preventive care recommendations remains a point of interest for healthcare providers and policy stakeholders, particularly given ongoing debates regarding the composition and influence of federal health advisory panels.

More stories

Latest news